We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

16 hedge funds and large institutions have $336K invested in Biolase, Inc. in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

68% more capital invested

Capital invested by funds: $199K → $336K (+$136K)

33% more funds holding

Funds holding: 12 → 16 (+4)

Holders
16
Holders Change
+4
Holders Change %
+33.33%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$191K
2
KWA
Kellett Wealth Advisors
Ohio
+$27.2K
3
Citadel Advisors
Citadel Advisors
Florida
+$19.7K
4
VF
Virtu Financial
New York
+$17.6K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$15.6K

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$31.5K
2
Bank of America
Bank of America
North Carolina
-$26
3
IA
IFP Advisors
Florida
-$6
4
Morgan Stanley
Morgan Stanley
New York
-$4

BIOL Hedge Fund Activity: Q4 2023 in Review

16 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q4 2023, worth a combined $336K — up 68% from $199K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BIOL positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Anson Funds Management, adding an estimated $191K. The largest seller was Walleye Capital, exiting entirely with an estimated $31.5K sold.

  • 16 institutional investors held Biolase, Inc. (BIOL) as of Q4 2023, up from 12 in Q3 2023.
  • Funds reported $336K of Biolase, Inc. stock for Q4 2023, up 68% quarter-over-quarter.
  • 6 funds opened new Biolase, Inc. positions in Q4 2023 and 2 closed out, a net change of +4 holders.
  • The largest Biolase, Inc. buyer in Q4 2023 was Anson Funds Management, an estimated $191K added.
  • The largest Biolase, Inc. seller in Q4 2023 was Walleye Capital, an estimated $31.5K sold.

Based on aggregated 13F filings for Q4 2023.